ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 831,55
0,06%
DAX
18 726,76
-0,21%
Brent Oil
82,765
-0,92%
Bitcoin
69 815,22
-2,29%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Micro Therapeutics (MM) (MTIX)

  7. Micro Therapeutics (MM) (MTIX) Actualités

MTIX

Micro Therapeutics (MTIX)

Micro Therapeutics (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MTIX
DateHeureSourceTitreSymboleSociété
08/12/200517h01PR Newswire (US)ev3 Inc. Announces Expected Closing Date for Acquisition of Public Minority Stake in Micro Therapeutics, Inc.NASDAQ:MTIXMicro Therapeutics (MM)
14/11/200515h11PR Newswire (US)ev3 Inc. and Micro Therapeutics, Inc. Announce Merger AgreementNASDAQ:MTIXMicro Therapeutics (MM)
27/10/200515h01PR Newswire (US)Micro Therapeutics Reports 72% Increase in 2005 Third Quarter Net SalesNASDAQ:MTIXMicro Therapeutics (MM)
27/10/200515h00PR Newswire (US)ev3 Inc. Reports Third Quarter Financial ResultsNASDAQ:MTIXMicro Therapeutics (MM)
21/10/200516h00PR Newswire (US)ev3 and Micro Therapeutics to Report 2005 Third-Quarter Financial Results and Host Joint Conference Call on October 27, 2005NASDAQ:MTIXMicro Therapeutics (MM)
10/10/200516h30PR Newswire (US)ev3 Inc. Proposes to Acquire Public Minority Stake in Micro Therapeutics, Inc.NASDAQ:MTIXMicro Therapeutics (MM)
10/10/200515h30PR Newswire (US)Micro Therapeutics, Inc. Announces Receipt of Exchange Offer Proposal From ev3 Inc.NASDAQ:MTIXMicro Therapeutics (MM)
05/10/200520h04PR Newswire (US)Micro Therapeutics, Inc. Reports Sales Results for Third Quarter 2005NASDAQ:MTIXMicro Therapeutics (MM)
02/08/200523h51PR Newswire (US)Micro Therapeutics Reports 44% Increase in Net Sales for 2005 Second Quarter; Company Raises Sales Guidance for 2005NASDAQ:MTIXMicro Therapeutics (MM)
02/08/200523h48PR Newswire (US)ev3 Inc. Reports Second Quarter Financial ResultsNASDAQ:MTIXMicro Therapeutics (MM)
27/07/200522h27PR Newswire (US)ev3 and Micro Therapeutics to Report 2005 Second Quarter Financial Results and Host Joint Conference Call on August 2, 2005NASDAQ:MTIXMicro Therapeutics (MM)
22/07/200500h27PR Newswire (US)ev3 Inc. Announces FDA Approval of Onyx(R) for the Treatment of Brain Vascular DisorderNASDAQ:MTIXMicro Therapeutics (MM)
22/07/200500h08PR Newswire (US)Micro Therapeutics Announces FDA Approval of Onyx(R) for the Treatment of Brain Vascular DisorderNASDAQ:MTIXMicro Therapeutics (MM)
07/07/200500h30PR Newswire (US)Micro Therapeutics, Inc. Reports Sales Results for Second Quarter 2005NASDAQ:MTIXMicro Therapeutics (MM)
28/04/200523h14PR Newswire (US)Micro Therapeutics Reports 50% Net Sales Increase for 2005 First QuarterNASDAQ:MTIXMicro Therapeutics (MM)
25/04/200519h28PR Newswire (US)Micro Therapeutics to Report First Quarter Financial Results and Host Conference Call on April 28, 2005NASDAQ:MTIXMicro Therapeutics (MM)
21/03/200522h57PR Newswire (US)ev3 Announces Enrollment Has Begun for SpideRX(TM) Embolic Protection Device in Second Phase of Carotid Clinical TrialNASDAQ:MTIXMicro Therapeutics (MM)
10/02/200521h23PR Newswire (US)Micro Therapeutics Reports Record Revenue in 2004 Fourth Quarter and Full Year Financial ResultsNASDAQ:MTIXMicro Therapeutics (MM)
10/02/200513h45PR Newswire (US)Reminder - Micro Therapeutics to Report 2004 Fourth Quarter and Full Year Financial Results and Host Conference Call on FebruaryNASDAQ:MTIXMicro Therapeutics (MM)
08/02/200500h40PR Newswire (US)Micro Therapeutics to Report 2004 Fourth Quarter and Full Year Financial Results and Host Conference Call on February 10, 2005NASDAQ:MTIXMicro Therapeutics (MM)
01/02/200513h00PR Newswire (US)Micro Therapeutics Receives $3.7 Million PaymentNASDAQ:MTIXMicro Therapeutics (MM)
29/12/200418h13PR Newswire (US)Micro Therapeutics Consolidates Manufacturing CapabilitiesNASDAQ:MTIXMicro Therapeutics (MM)
06/12/200421h04PR Newswire (US)ev3 Receives Investigational Device Exemption for Use of SpideRX(TM) Embolic Protection Device in Clinical TrialNASDAQ:MTIXMicro Therapeutics (MM)
10/11/200415h00PR Newswire (US)ev3 International Files Lawsuit Against Distributors in Hong Kong and PhoenixNASDAQ:MTIXMicro Therapeutics (MM)
04/11/200413h00PR Newswire (US)Micro Therapeutics Reports 2004 Third Quarter Financial ResultsNASDAQ:MTIXMicro Therapeutics (MM)
01/11/200421h24PR Newswire (US)Micro Therapeutics to Report 2004 Third Quarter Financial Results and Host Conference Call on November 4NASDAQ:MTIXMicro Therapeutics (MM)
21/10/200417h47PR Newswire (US)FDA Grants Marketing Clearance to ev3 for Protege(R) GPS(TM) Long StentsNASDAQ:MTIXMicro Therapeutics (MM)
21/09/200415h01PR Newswire (US)ev3(TM) Receives 510(k) Marketing Clearance for X-SIZER(R) Thrombectomy Catheter System for Dialysis Graft UseNASDAQ:MTIXMicro Therapeutics (MM)
26/08/200418h33PR Newswire (US)ev3 Receives CE Mark Approval for Tapered Stents for Carotid Stenting ProceduresNASDAQ:MTIXMicro Therapeutics (MM)
18/08/200419h51PR Newswire (US)Micro Therapeutics Completes Issuance of Common Stock for Exchangeable NotesNASDAQ:MTIXMicro Therapeutics (MM)
 Showing the most relevant articles for your search:NASDAQ:MTIX

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
EU
EN
Bouygues
USI
USTECH100
US Tech 100
EU
CAP
Capgemini
EU
SGO
Cie de SaintGobain
EU
LR
Legrand
NYSE
DIS
Walt Disney
NASDAQ
AAPL
Apple
SPI
SP500
S&P 500
NYSE
JPM
JP Morgan Chase
FTSE
UKX
FTSE 100
NASDAQ
GOOGL
Alphabet
EU
BEL20
Bel 20
EU
VK
Vallourec
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés